Donepezil

Generic Name: Donepezil

Brand Names: Adlarity, Aricept, Namzaric

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₉NO_₃

CAS Number: 120014-06-4

Unique Ingredient Identifier: 8SSC91326P

Background: In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...

Indication: Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...

Associated Conditions: Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia

Associated Therapies: -

Clinical Trials

To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer´s Disease

Interventions: Drug: AZD1446
Drug: Placebo
Drug: Donepezil

First Posted Date: 2010-05-18

Last Posted Date: 2011-05-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 40

Registration Number: NCT01125683

Locations: 🇺🇦
Research Site, Vinnytsia, Ukraine

Randomized Controlled Study of Donepezil in Fragile X Syndrome

Phase 2

Completed

Conditions: Fragile X Syndrome

Interventions: Drug: sugar pill
Drug: donepezil

First Posted Date: 2010-05-11

Last Posted Date: 2016-03-17

Lead Sponsor: Stanford University

Target Recruit Count: 45

Registration Number: NCT01120626

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

Not Applicable

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Donepezil
Drug: Placebo

First Posted Date: 2010-03-09

Last Posted Date: 2013-09-12

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT01082965

Locations: 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States

A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition

Phase 1

Completed

Conditions: Cognition

Interventions: Drug: AZD1446
Drug: Placebo
Drug: donepezil

First Posted Date: 2010-01-07

Last Posted Date: 2010-05-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 20

Registration Number: NCT01044342

Locations: 🇫🇷
Research Site, Rouffach, France

Drug-Drug Interaction Study With Aricept® (Donepezil)

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Donepezil
Drug: BMS-708163

First Posted Date: 2010-01-05

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT01042314

Locations: 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States

The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil

Early Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Donepezil
Drug: Placebo to match Aricept

First Posted Date: 2009-12-03

Last Posted Date: 2011-02-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 155

Registration Number: NCT01024660

Locations: 🇿🇦
Research Site, Roodepoort, South Africa
🇨🇦
Reearch Site, Quebec, Canada

Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia

Not Applicable

Completed

Conditions: Alzheimer's Disease
Dementia

Interventions: Drug: donepezil

First Posted Date: 2009-12-02

Last Posted Date: 2016-01-06

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 88

Registration Number: NCT01023867

Locations: 🇰🇷
Samsung Medical Center, Seoul City, Korea, Republic of

Clinical Trial of Donepezil Between the Naive Group and the Switching Group

Not Applicable

Completed

Conditions: Dementia
Alzheimer's Disease

Interventions: Drug: donepezil

First Posted Date: 2009-12-02

Last Posted Date: 2016-01-06

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 72

Registration Number: NCT01023425

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: ABT-288
Drug: donepezil
Drug: placebo

First Posted Date: 2009-11-24

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 242

Registration Number: NCT01018875

Locations: 🇺🇦
Site Reference ID/Investigator# 24565, Kherson, Ukraine
🇷🇺
Site Reference ID/Investigator# 22636, Moscow, Russian Federation
🇷🇺
Site Reference ID/Investigator# 22635, St. Petersburg, Russian Federation

and more 18 locations

Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease

Phase 3

Terminated

Conditions: Parkinson's Disease

Interventions: Drug: Donepezil

First Posted Date: 2009-11-17

Last Posted Date: 2017-09-25

Lead Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust

Target Recruit Count: 64

Registration Number: NCT01014858

Locations: 🇬🇧
Newcastle, Newcastle Upon Tyne, Tyne and Wear, United Kingdom
🇬🇧
Cambridge Centre for Brain Repair, Cambridge, United Kingdom
🇬🇧
Royal Bournemouth & Christchurch Hospitals NHS Foundation Trust, Dorset, United Kingdom

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy